Sampath Anand 4
4 · MASIMO CORP · Filed Jan 30, 2026
Research Summary
AI-generated summary of this filing
Masimo (MASI) EVP Sampath Anand Exercises Options, Sells Shares
What Happened
- Sampath Anand, EVP of Operations & Clinical Research at Masimo (MASI), exercised 30,000 stock options at $37.84 per share (cost $1,135,200) on January 28, 2026. The filing also reports open‑market sales of 11,924, 6,560 and 196 shares (total 18,680 shares) for aggregate proceeds of about $2,555,570. The Form 4 shows an additional 30,000‑share derivative entry (reported at $0.00) associated with the exercise/conversion.
Key Details
- Transaction date: 2026-01-28; Form filed 2026-01-30 (timely).
- Exercise: 30,000 shares at $37.84 = $1,135,200.
- Sales (open market):
- 11,924 shares @ $136.56 = $1,628,341 (weighted avg; actuals ranged $135.94–$136.94).
- 6,560 shares @ $137.22 = $900,163 (weighted avg; actuals ranged $136.95–$137.89).
- 196 shares @ $138.09 = $27,066 (weighted avg; actuals ranged $138.07–$138.12).
- Total reported sale proceeds (these three trades): ≈ $2,555,570.
- Shares owned after the transactions: not specified in the provided filing details.
- Notable footnotes:
- F1: Transactions were executed pursuant to a Rule 10b5‑1 sales plan dated Sept 12, 2025.
- F2–F4: Reported prices are weighted averages; price ranges given for each sale block.
- F5: Option was originally granted Feb 29, 2016 and vested over five years.
- Filing timeliness: Report filed within two business days of the transaction date (no late filing indicated).
Context
- This filing shows an option exercise combined with immediate sales under a 10b5‑1 plan — a common way executives convert options to cash while following a pre‑arranged trading plan. The presence of a derivative (M) line and zero‑dollar entry reflects reporting of the option conversion; the separate open‑market sale lines show shares actually sold for cash. These types of transactions are routine and required to be reported, but they do not, by themselves, indicate the insider’s current sentiment about the company.
Insider Transaction Report
Form 4
MASIMO CORPMASI
Sampath Anand
EVP, Operations
Transactions
- Exercise/Conversion
Common Stock
2026-01-28$37.84/sh+30,000$1,135,200→ 59,589 total - Sale
Common Stock
[F1][F2]2026-01-28$136.56/sh−11,924$1,628,341→ 47,665 total - Sale
Common Stock
[F1][F3]2026-01-28$137.22/sh−6,560$900,163→ 41,105 total - Sale
Common Stock
[F1][F4]2026-01-28$138.09/sh−196$27,066→ 40,909 total - Exercise/Conversion
Non-Qualified Stock Option (Right to Buy)
[F5]2026-01-28−30,000→ 0 totalExercise: $37.84Exp: 2026-03-01→ Common Stock (30,000 underlying)
Footnotes (5)
- [F1]The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of September 12, 2025, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $135.94 per share to a high of $136.94 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F3]The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $136.95 per share to a high of $137.89 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F4]The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $138.07 per share to a high of $138.12 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F5]This option was granted on February 29, 2016 and is exercisable as the option vests. The option vested over a 5 year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.
Signature
/s/ Micah W. Young, Attorney-In-Fact|2026-01-30